Supportive care in pediatric oncology: Oncologic emergencies and management of fever and neutropenia

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 27-46

  Henry, Meret ^a   Sung, Lillian ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer; Early signs of childhood cancer; Fever; Infection; Neutropenia; Oncologic emergencies

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BLOOD CULTURE; CARE AND CARING; CHILD CARE; CHILDHOOD CANCER; CLINICAL FEATURE; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; FEVER; HUMAN; LEUKOCYTOSIS; MEDIASTINUM DISEASE; MONOTHERAPY; NEUTROPENIA; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SPINAL CORD COMPRESSION; SUPERIOR CAVA VEIN SYNDROME; SUPERIOR MEDIASTINAL SYNDROME; SUPPORTIVE CARE; SYSTEMIC MYCOSIS; TUMOR LYSIS SYNDROME; URINALYSIS; CHILD; EMERGENCY; ONCOLOGY; PEDIATRICS;

ANTI-BACTERIAL AGENTS; CHILD; EMERGENCIES; FEVER; HUMANS; MEDICAL ONCOLOGY; NEUTROPENIA; PEDIATRICS;

EID: 84915751177     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.016     Document Type: Review

References (116)

1. Inaba H., Fan Y., Pounds S., et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer 2008, 113(3):522-529.
2. Lowe E.J., Pui C.H., Hancock M.L., et al. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 2005, 45(1):10-15.
3. Sung L., Aplenc R., Alonzo T.A., et al. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica 2012, 97(11):1770-1773.
4. Eguiguren J.M., Schell M.J., Crist W.M., et al. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992, 79(4):871-875.
5. Porcu P., Farag S., Marcucci G., et al. Leukocytoreduction for acute leukemia. Ther Apher 2002, 6(1):15-23.
6. Lichtman M.A., Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982, 60(2):279-283.
7. Porcu P., Cripe L.D., Ng E.W., et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000, 39(1-2):1-18.
8. Stucki A., Rivier A.S., Gikic M., et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001, 97(7):2121-2129.
9. Kong S.G., Seo J.H., Jun S.E., et al. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood Res 2014, 49(1):29-35.
10. Tryka A.F., Godleski J.J., Fanta C.H. Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia. Cancer 1982, 50(12):2763-2770.
11. Castro-Malaspina H., Schaison G., Briere J., et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors. Cancer 1983, 52(4):721-727.
12. Millot F., Traore P., Guilhot J., et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005, 116(1):140-143.
13. Rowe J.M., Lichtman M.A. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood 1984, 63(5):1230-1234.
14. Chen K.H., Liu H.C., Liang D.C., et al. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. JFormos Med Assoc 2014, [Epub ahead of print].
15. Bunin N.J., Pui C.H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. JClin Oncol 1985, 3(12):1590-1595.
16. Maurer H.S., Steinherz P.G., Gaynon P.S., et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. JClin Oncol 1988, 6(9):1425-1432.
17. Ganzel C., Becker J., Mintz P.D., et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012, 26(3):117-122.
18. Greze V., Chambon F., Merlin E., et al. Leukapheresis in management of hyperleukocytosis in children's leukemias. JPediatr Hematol Oncol 2014, [Epub ahead of print].
19. Oberoi S., Lehrnbecher T., Phillips B., et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res 2014, 38(4):460-468.
20. Pastore F., Pastore A., Wittmann G., et al. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One 2014, 9(4):e95062.
21. Azoulay E., Canet E., Raffoux E., et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. Eur Respir J 2012, 39(3):648-653.
22. Moreau A.S., Lengline E., Seguin A., et al. Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma 2014, [Epub ahead of print].
23. Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome. NEngl J Med 2011, 364(19):1844-1854.
24. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127(1):3-11.
25. Cairo M.S., Coiffier B., Reiter A., TLS Expert Panel, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010, 149(4):578-586.
26. Coiffier B., Altman A., Pui C.H., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. JClin Oncol 2008, 26(16):2767-2778.
27. Galardy P.J., Hochberg J., Perkins S.L., et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Br J Haematol 2013, 163(3):365-372.
28. Pession A., Masetti R., Gaidano G., et al. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. Adv Ther 2011, 28(8):684-697.
29. Pui C.H., Mahmoud H.H., Wiley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. JClin Oncol 2001, 19(3):697-704.
30. Cairo M.S., Gerrard M., Sposto R., et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109(7):2736-2743.
31. Sonbol M.B., Yadav H., Vaidya R., et al. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol 2013, 88(2):152-154.
32. Agrawal A.K., Feusner J.H. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?. Br J Haematol 2011, 153(2):275-277.
33. Coutsouvelis J., Wiseman M., Hui L., et al. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 2013, 75(2):550-553.
34. Knoebel R.W., Lo M., Crank C.W. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. JOncol Pharm Pract 2011, 17(3):147-154.
35. Janin Y., Becker J., Wise L., et al. Superior vena cava syndrome in childhood and adolescence: a review of the literature and report of three cases. JPediatr Surg 1982, 17(3):290-295.
36. Ingram L., Rivera G.K., Shapiro D.N. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 1990, 18(6):476-481.
37. Pizzo P., Poplack D. Principles and practice of pediatric oncology 2011, Lippincott, Williams & Wilkins, Philadelphia. 6th edition.
38. Wilson L.D., Detterbeck F.C., Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. NEngl J Med 2007, 356(18):1862-1869.
39. Stricker P.A., Gurnaney H.G., Litman R.S. Anesthetic management of children with an anterior mediastinal mass. JClin Anesth 2010, 22(3):159-163.
40. Sola C., Choquet O., Prodhomme O., et al. Management of mediastinal syndromes in pediatrics: a new challenge of ultrasound guidance to avoid high-risk general anesthesia. Paediatr Anaesth 2014, 24(5):534-537.
41. Borenstein S.H., Gerstle T., Malkin D., et al. The effects of prebiopsy corticosteroid treatment on the diagnosis of mediastinal lymphoma. JPediatr Surg 2000, 35(6):973-976.
42. Issa P.Y., Brihi E.R., Janin Y., et al. Superior vena cava syndrome in childhood: report of ten cases and review of the literature. Pediatrics 1983, 71(3):337-341.
43. Klein S.L., Sanford R.A., Muhlbauer M.S. Pediatric spinal epidural metastases. JNeurosurg 1991, 74(1):70-75.
44. Tantawy A.A., Ebeid F.S., Mahmoud M.A., et al. Spinal cord compression in childhood pediatric malignancies: multicenter Egyptian study. JPediatr Hematol Oncol 2013, 35(3):232-236.
45. Mora J., Wollner N. Primary epidural non-Hodgkin lymphoma: spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma. Med Pediatr Oncol 1999, 32(2):102-105.
46. Pashankar F.D., Steinbok P., Blair G., et al. Successful chemotherapeutic decompression of primary endodermal sinus tumor presenting with severe spinal cord compression. JPediatr Hematol Oncol 2001, 23(3):170-173.
47. Daley M.F., Partington M.D., Kadan-Lottick N., et al. Primary epidural Burkitt lymphoma in a child: case presentation and literature review. Pediatr Hematol Oncol 2003, 20(4):333-338.
48. Meltzer J.A., Jubinsky P.T. Acute myeloid leukemia presenting as spinal cord compression. Pediatr Emerg Care 2005, 21(10):670-672.
49. Gupta V., Srivastava A., Bhatia B. Hodgkin disease with spinal cord compression. JPediatr Hematol Oncol 2009, 31(10):771-773.
50. Cole J.S., Patchell R.A. Metastatic epidural spinal cord compression. Lancet Neurol 2008, 7(5):459-466.
51. De Bernardi B., Pianca C., Pistamiglio P., et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. JClin Oncol 2001, 19(1):183-190.
52. Walter K.N., Kratz C., Uhl M., et al. Chemotherapy as a therapeutic option for congenital neuroblastoma complicated by paraplegia. Klin Padiatr 2008, 220(3):175-177.
53. Capasso M., Cinalli G., Nastro A., et al. Symptomatic epidural compression in infants with neuroblastoma: a single-center experience with 5 cases. JPediatr Hematol Oncol 2013, 35(4):260-266.
54. Angelini P., Plantaz D., De Bernardi B., et al. Late sequelae of symptomatic epidural compression in children with localized neuroblastoma. Pediatr Blood Cancer 2011, 57(3):473-480.
55. Simon T., Niemann C.A., Hero B., et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012, 54(4):347-352.
56. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64(2):328-340.
57. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J 2008, 27(6):538-543.
58. Schimpff S., Satterlee W., Young V.M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. NEngl J Med 1971, 284(19):1061-1065.
59. Pizzo P.A. Management of fever in patients with cancer and treatment-induced neutropenia. NEngl J Med 1993, 328(18):1323-1332.
60. Lehrnbecher T., Phillips R., Alexander S., et al. Guideline for the Managementof Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. JClin Oncol 2012, 30(35):4427-4438.
61. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. JClin Oncol 2000, 18(16):3038-3051.
62. Phillips R.S., Lehrnbecher T., Alexander S., et al. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 2012, 7(5):e38300.
63. Alexander S.W., Wade K.C., Hibberd P.L., et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. JPediatr Hematol Oncol 2002, 24(1):38-42.
64. Ammann R.A., Bodmer N., Hirt A., et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. JClin Oncol 2010, 28(12):2008-2014.
65. Ammann R.A., Hirt A., Luthy A.R., et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003, 41(5):436-443.
66. Rackoff W.R., Gonin R., Robinson C., et al. Predicting the risk of bacteremia in children with fever and neutropenia. JClin Oncol 1996, 14(3):919-924.
67. Rondinelli P.I., Ribeiro Kde C., de Camargo B. Aproposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. JPediatr Hematol Oncol 2006, 28(10):665-670.
68. Santolaya M.E., Alvarez A.M., Becker A., et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. JClin Oncol 2001, 19(14):3415-3421.
69. Barriga F.J., Varas M., Potin M., et al. Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol 1997, 28(3):196-200.
70. Handrup M.M., Moller J.K., Schroder H. Catheter-related bloodstream infections in children with cancer admitted with fever. 42nd Congress of the International Society of Pediatric Oncology (SIOP) 2010, Pediatr Blood Cancer, Boston.
71. Raad I., Hanna H.A., Alakech B., et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004, 140(1):18-25.
72. Adamkiewicz T.V., Lorenzana A., Doyle J., et al. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999, 18(6):556-558.
73. DesJardin J.A., Falagas M.E., Ruthazer R., et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 1999, 131(9):641-647.
74. Scheinemann K., Ethier M.C., Dupuis L.L., et al. Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer 2010, 18(8):913-919.
75. Chen W.T., Liu T.M., Wu S.H., et al. Improving diagnosis of central venous catheter-related bloodstream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital. JInfect 2009, 59(5):317-323.
76. Wilson M.L., Mitchell M., Morris A.J., et al. Principles and procedures for blood cultures; Approved guideline. CLSI document M47-A 2007, vol. 27. Clinical and Laboratory Standards Institute, Wayne (PA), (17).
77. Klaassen I.L., de Haas V., van Wijk J.A., et al. Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 2011, 56(5):868-870.
78. Mori R., Yonemoto N., Fitzgerald A., et al. Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy. Acta Paediatr 2010, 99(4):581-584.
79. Renoult E., Buteau C., Turgeon N., et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer?. Pediatr Blood Cancer 2004, 43(3):224-228.
80. Korones D.N., Hussong M.R., Gullace M.A. Routine chest radiography of children with cancer hospitalized for fever and neutropenia: is it really necessary?. Cancer 1997, 80(6):1160-1164.
81. Feusner J., Cohen R., O'Leary M., et al. Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. JClin Oncol 1988, 6(11):1699-1702.
82. Katz J.A., Bash R., Rollins N., et al. The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia. Cancer 1991, 68(5):940-943.
83. Phillips B., Wade R., Westwood M., et al. Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. JPaediatr Child Health 2012, 48(8):641-648.
84. Furno P., Bucaneve G., Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002, 2(4):231-242.
85. Paul M., Soares-Weiser K., Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326(7399):1111.
86. Manji A., Lehrnbecher T., Dupuis L.L., et al. Asystematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer 2012, 20(10):2295-2304.
87. Paul M., Yahav D., Bivas A., et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010, (11). CD005197.
88. Manji A., Lehrnbecher T., Dupuis L.L., et al. Ameta-analysis of anti-pseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia. Pediatr Infect Dis J 2012, 31(4):353-358.
89. Kim P.W., Wu Y.T., Cooper C., et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010, 51(4):381-389.
90. Marron A., Carratala J., Alcaide F., et al. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. JAntimicrob Chemother 2001, 47(1):87-91.
91. Vardakas K.Z., Samonis G., Chrysanthopoulou S.A., et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5(7):431-439.
92. Oude Nijhuis C., Kamps W.A., Daenen S.M., et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. JClin Oncol 2005, 23(30):7437-7444.
93. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52(4):e56-e93.
94. Ammann R.A., Simon A., de Bont E.S. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?. Pediatr Blood Cancer 2005, 45(3):244-247.
95. Speyer E., Herbinet A., Vuillemin A., et al. Agreement between children with cancer and their parents in reporting the child's health-related quality of life during a stay at the hospital and at home. Child Care Health Dev 2009, 35(4):489-495.
96. Teuffel O., Amir E., Alibhai S.M., et al. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 2011, 127(2):e279-e286.
97. Kamboj M., Sepkowitz K.A. Nosocomial infections in patients with cancer. Lancet Oncol 2009, 10(6):589-597.
98. El-Mahallawy H.A., El-Wakil M., Moneer M.M., et al. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011, 57(2):283-288.
99. Teuffel O., Ethier M.C., Alibhai S.M., et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 2011, 22(11):2358-2365.
100. Manji A., Beyene J., Dupuis L.L., et al. Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children-a systematic review of prospective trials. Support Care Cancer 2012, 20(6):1135-1145.
101. Vidal L., Paul M., Ben-Dor I., et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004, (4). CD003992.
102. Cheng S., Teuffel O., Ethier M.C., et al. Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia. Br J Cancer 2011, 105(5):606-611.
103. Sung L., Feldman B.M., Schwamborn G., et al. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. JClin Oncol 2004, 22(19):3922-3929.
104. Sung L., Alibhai S.M., Ethier M.C., et al. Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. JClin Epidemiol 2012, 65(6):627-634.
105. Diorio C., Martino J., Boydell K.M., et al. Parental perspectives on inpatient versus outpatient management of pediatric febrile neutropenia. JPediatr Oncol Nurs 2011, 28(6):355-362.
106. Tran T.H., Mitchell D., Dix D., et al. Infections in children with Down syndrome and acute myeloid leukemia: a report from the Canadian Infections in AML Research Group. Infect Agent Cancer 2013, 8(1):47.
107. Cometta A., Kern W.V., De Bock R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003, 37(3):382-389.
108. Santolaya M.E., Villarroel M., Avendano L.F., et al. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 1997, 25(1):92-97.
109. Pizzo P.A., Robichaud K.J., Gill F.A., et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979, 67(2):194-200.
110. Agrawal A.K., Saini N., Gildengorin G., et al. Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies?. Pediatr Blood Cancer 2011, 57(4):620-624.
111. Burgos A., Zaoutis T.E., Dvorak C.C., et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008, 121(5):e1286-e1294.
112. Taccone A., Occhi M., Garaventa A., et al. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 1993, 23(3):177-180.
113. Archibald S., Park J., Geyer J.R., et al. Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J 2001, 20(1):5-10.
114. Prentice H.G., Hann I.M., Herbrecht R., et al. Arandomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98(3):711-718.
115. Maertens J.A., Madero L., Reilly A.F., et al. Arandomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010, 29(5):415-420.
116. Sandler E.S., Mustafa M.M., Tkaczewski I., et al. Use of amphotericin B colloidal dispersion in children. JPediatr Hematol Oncol 2000, 22(3):242-246.